Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 11/20 | 0.56 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436320 | 0.86 | CYP46A1 (0.55) | CYP46A1PDK2AKR1C3 | |
| SCHEMBL17452148 | 0.82 | CYP46A1 (0.51) | NOTUMCYP46A1PDK2 | |
| SCHEMBL4889125 | 0.81 | NOTUM (0.58) | NOTUMCYP46A1PDK2 | |
| SCHEMBL5800932 | 0.80 | NOTUM (0.81) | NOTUMGAAAKR1C3 | |
| SCHEMBL4404327 | 0.79 | NOTUM (0.49) | NOTUMCYP46A1PDK2 | |
| SCHEMBL8124395 | 0.79 | GAA (0.69) | NOTUMMALT1GAAAKR1C3 | |
| SCHEMBL28849115 | 0.78 | ALDH1A1 (0.65) | NOTUMMALT1 | |
| SCHEMBL21447981 | 0.77 | ADRB1 (0.50) | NOTUMGAA | |
| SCHEMBL2261436 | 0.76 | CYP3A4 (0.67) | NOTUMCYP46A1 | |
| SCHEMBL19667078 | 0.75 | NOTUM (0.69) | NOTUMCYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | NOTUM 1057/4885CYP46A1 1783/4885MALT1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.